Portland State University

PDXScholar
Community Health Faculty Publications and
Presentations

School of Community Health

2011

Morinda Citrifolia L. (noni) Improves the Quality of
Life in Adults with Osteoarthritis
Mian-Ying Wang
University of Illinois College of Medicine at Rockford

M. Nawal Lutfiyya
Essentia Institute of Rural Health

Vicki Weidenbacher-Hoper
Essentia Institute of Rural Health

Lin Peng
University of Illinois College of Medicine at Rockford

Martin S. Lipsky
Portland State University

See next page for additional authors
Follow this and additional works at: https://pdxscholar.library.pdx.edu/commhealth_fac
Part of the Alternative and Complementary Medicine Commons, and the Natural Products Chemistry
and Pharmacognosy Commons

Let us know how access to this document benefits you.
Citation Details
Wang, M. Y., Lutfiyya, M. N., Weidenbacher-Hoper, V., Peng, L., Lipsky, M. S., & Anderson, G. (2011).
Morinda citrifolia L.(noni) improves the Quality of Life in adults with Osteoarthritis. Functional Foods in
Health and Disease, 1(2), 75-90.

This Article is brought to you for free and open access. It has been accepted for inclusion in Community Health
Faculty Publications and Presentations by an authorized administrator of PDXScholar. Please contact us if we can
make this document more accessible: pdxscholar@pdx.edu.

Authors
Mian-Ying Wang, M. Nawal Lutfiyya, Vicki Weidenbacher-Hoper, Lin Peng, Martin S. Lipsky, and Gary
Anderson

This article is available at PDXScholar: https://pdxscholar.library.pdx.edu/commhealth_fac/80

Functional Foods in Health and Disease 2011, 1(2):75-90

Research

Page 75 of 90

Open Access

Morinda citrifolia L. (noni) improves the Quality of Life in adults with
Osteoarthritis
1

Mian-Ying Wang, 3M. Nawal Lutfiyya, 2Vicki Weidenbacher-Hoper, 1Lin Peng, 2Martin S.
Lipsky, and 1Gary Anderson
1

Department of Pathology and 2Department of Family and Community Medicine, University of
Illinois College of Medicine at Rockford, 1601 Parkview Avenue, Rockford, IL 61107, USA. 3
Essentia Institute of Rural Health, 502 East 2nd Street, Duluth, MN 55805, USA
Running title: Noni improves the QoL of adults with osteoarthritis
Corresponding Author: Mian-Ying Wang, MD,
Department of Pathology,
University of Illinois College of Medicine at Rockford
1601 Parkview Ave, Rockford, IL 61107, USA
Submission date: 24 January 2011, Acceptance date: 20 February 2011, Publication date: 20
February 2011

Abstract
Background: Morinda citrifolia Linn (noni), as a “pain killer”, has been used as a traditional
medicine by Polynesians for over 2000 years. It was reported to have a broad range of
therapeutic effects including analgesic and anti-inflammation. The in-vitro and in vivo antiinflammatory and analgesic properties of noni juice (NJ) suggest that NJ may be a useful
adjunctive treatment for osteoarthritis (OA). In this pilot study we explored whether NJ
improves the symptoms and Quality of Life (QoL) for adults with OA. We also sought to
evaluate the tolerability and safety of NJ for patients with OA in a primary care setting.
Methods: This was an open label three-month intervention pilot study. Data were collected by
pre/post intervention survey and laboratory testing. Inclusion criteria were: adults of both sexes
aged 40 to 75, with a diagnosis of OA on the hip or knee by x-ray examination provided by their
primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz
of NJ a day for 90 days.
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Results: Of the 64 questions measuring different aspects of QoL asked on the pre/post survey,
49 (77%) had significant pre/post mean scale differences as measured by independent t-test. The
OA patients reported being significantly more satisfied with their current health conditions
including mobility, walking and bending, hand, finger, and arm functions, household tasks,
social activity, arthritis pain, work ability, level of tension, and mood. The study participants
were also more positive about their future health and reported taking less over-the-counter (OTC)
pain relievers. Pre/post laboratory testing including: lipid panel, liver and kidney functions were
in the normal ranges. High Sensitive C Reactive Protein (hsCRP), an inflammatory biomarker,
was reduced by 10% after the intervention.
Conclusion: As a nutritional supplement, NJ demonstrated a potential therapeutic effect and
improved the symptoms and the QoL for adults with OA. A larger, double blinded, and placebo
controlled clinical trial study is needed to confirm these benefits. NJ has the potential to become
an adjunctive therapy for OA patients.
Clinical trial registration number: NCT01070264.
Key words:
Morinda citrifolia (noni), Noni juice (NJ), Osteoarthritis, Quality of
life (QoL), pain scales

Background
Approximately 10% of people in the U.S. have OA, making it the most common form of arthritis
and one of the most prevalent chronic diseases in western countries. For people older than 75 the
estimated prevalence of OA rises to between 70 - 90% [1].
While the etiology of OA is multi-factorial, the condition results from the gradual
degeneration of joint cartilage. Joint cartilage normally cushions the bones in a joint and if
damaged causes bone overgrowth and fragmentation of the cartilage which can lead to
inflammation, pain and functional impairment. As a result it is not surprising that OA is a leading
cause of disability and that between 10 to 30 % of those affected with OA suffer from significant
pain and disability [2-6].
Disease modifying treatments that halt the progression of OA remain elusive and as a
result current management focuses on reducing symptoms [7]. These include interventions such
as weight loss, exercise, analgesics, steroid joint injections, joint replacement and medications
[8]. Non-steroid anti-inflammatory drugs [NSAIDs] are one type of medication though widely
used for symptoms, have a significant side effect profile that compromises their benefits. While
selective cyclooxygenase (Cox-2) inhibitors provide symptom relief with reduced GI side
effects, an associated increase in the risk of cardiovascular disease led to several of these drugs
being withdrawn from the market [9]. Due to a favorable safety profile many consider

Functional Foods in Health and Disease, 2: 75-90

Page 77 of 90

acetaminophen as drug of choice for OA; however, acetaminophen predominately affects pain
and may have only a modest benefit on improving function and relieving stiffness [10]. Faced
with these challenges, many patients and health providers turn to alternative methods [11]. One
viable alternative may be the complementary therapy of NJ made from Morinda citrifolia (noni)
fruits [12].
Several research studies support the rationale for the traditional use of NJ for treating
inflammatory and analgesic disorders [11, 13]. For decades, Polynesians have used noni for pain
and to reduce inflammation [14]. The specie Morinda citrifolia L. [noni] belongs to the genus
Morinda and the family Rubiaceae. Morinda includes about 80 species, of which noni is
considered the “queen” [15]. Studies examining noni reported that the noni fruit possesses
analgesic and tranquilizing activities [16]. An alcohol extract of noni fruit puree showed an
analgesic and anti-inflammatory effect by inhibiting MMP-9 release from human monocytes
after stimulation with lipopolysaccharides (LPS) and this effect was comparable to hydrocortisone. The authors claimed that preparations of noni fruits are effective in decreasing pain
and joint destruction caused by arthritis (17). Younis and his colleagues tested the analgesic and
sedative effects of noni extract and found “a significant, dose-related, central analgesic activity
in mice” and that “the analgesic efficacy of the noni extract was about 75% as strong as
morphine, yet non-addictive and side effect free [18]”. Research comparing the analgesic effect
of NJ to aspirin using hot-plate and twist assays in mice also supports NJ as a potentially
effective treatment for OA [19].
Additionally, an anti-inflammatory effect of NJ was observed in acute liver injury models
induced by CCl4 in female SD rats [20]. Other research revealed anti-oxidative activity that
scavenges reactive oxygen species (ROS) and quenches lipid peroxides (LPO) in smokers [21].
Of particular interest in terms of NJ’s potential as a therapeutic natural product for OA, is the
finding the NJ is a partial Cox-2 inhibitor in vitro with an inhibitory effect about 40% of the
effect of celexcoxib [22].
These research findings coupled with its traditional use as a treatment for pain suggest
that NJ might be an effective therapeutic nutritional supplement for OA patients. The goal of this
study was to conduct a preliminary exploration of NJ’s impact on the symptoms and QoL of OA
patients and at the same time to examine its tolerability and safety as a complimentary
therapeutic nutritional agent for OA.
Methods and Materials
This study was a 12-week open label pilot intervention study for individuals with OA to explore
the potential benefit of NJ for symptoms associated with OA. Research participants were
recruited consecutively and enrolled into the study until a targeted sample size of approximately
100 was reached. Pre/post intervention assessment was used to examine efficacy. The inclusion
criteria entailed: adults aged 40 to 75 of both sexes with X-ray diagnosis of OA of the hip or
knee who were not taking prescription medicine for arthritis and were willing to drink 3 oz of NJ
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daily for 90 days. The diagnostic criteria were deliberately set to mimic the real life clinical
setting in which NJ would most likely be used---a primary care physician diagnosis of OA for
those experiencing symptoms of OA proved by x-ray examination. Adults appearing to meet the
study’s eligibility criteria were interviewed by an experienced clinical coordinator to confirm
eligibility and to ensure that potential study participants were willing to complete all of the study
measures including blood draws. Informed consent was obtained from the participants once it
was ascertained that they met the enrollment criteria and were willing to participate.
To help ensure the intake of a daily dose of 3 oz of NJ, all enrolled study participants
were asked to drink 1 oz in the morning before breakfast, 1 oz before lunch, and 1 oz before
bedtime. Study participants picked up their one-month supply of NJ at the time of enrollment,
and again at the end of the first and then second month of the intervention. A 20 ml blood sample
for laboratory testing was drawn at enrollment and at the last visit. To confirm compliance with
the treatment protocol, the remaining NJ from the previous month’s supply was measured and
recorded. At the time of follow up, the study coordinator asked the study participants if they
were experiencing any new problems or symptoms that precluded their receiving the next NJ
allotment.
The clinical coordinator attempted to contact by phone anyone who failed to show up for
a follow up appointment. If a research participant failed to respond after 3 contacts or more than
30 days or missed 3 scheduled appointments they were dropped from the study. The NJ used in
this study was Tahitian Noni® juice donated by Morinda Holding Inc. The study was approved
by the University of Illinois-Chicago, College of Medicine at Rockford’s Institutional Review
Board.
At enrollment as baseline and then again at the end of the last visit, two validated
instruments were used to collect pre/post intervention study data on self-reported pain from QoL
associated with OA. The Arthritis Impact Measurement Scales [AIMS 2] were used to measure
self-reported pain in the study participants [23]. The Short Form-36 Version 2 [SF-36 V2] form
was used for the evaluation of QoL [24]. Both the AIMS 2 and the SF-36 V2 are validated
instruments [25]. Reliability and validity of the AIMS 2 have been well documented in arthritis
patients. The SF-36 V2 is both a multipurpose survey of general health status as well as a QoL
measure.
Some modifications, however, were made to the instruments. Due to the overlap of some
items on the AIMS 2 and the SF-36 V2, we combined the two forms into one questionnaire. The
AIMS 2 questionnaire includes 78 items used to establish severity of an individual’s clinical
status; these were included in the combined questionnaire. This instrument also contains
subscales for pain, stiffness, and function. The SF-36 questionnaire consists of several selfefficacy questions used to assess QoL. The QoL questions asked study participants to appraise
their current level of function and satisfaction, compared to what they perceive to be their ideal.
This assessment also asked study participants to express their ability to perform daily activities
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across multiple domains including: physical, social, cognitive functioning role activities, and
emotional well-being.
In addition to the two validated measures, another questionnaire was used to collect data
on patient characteristics such as age, gender, race, social status, and height and weight to
calculate body mass index [BMI], disease related characteristics [location of symptoms, duration
of symptoms, family history] and co-morbidities. Of these, BMI and co-morbidities were
monitored throughout the intervention study.
Statistical analysis
A power analysis was calculated for a two-tailed test of significance using a t-test for a medium
effect size, alpha was set at <0.05 and beta at .80. This analysis yielded that a sample size of 70
would be sufficient to detect possible significant differences pre/post intervention and a decision
was made to recruit approximately 100 study participants to assure a minimum of 70 subjects
when accounting for possible attrition.
Several statistical tests were used to determine if the NJ intervention yielded a significant
impact on the self-reported QoL measures for each study participant. Basic t-test analysis was
performed [26-27] with the differences in the primary outcomes [pain and function] measured
before and after the intervention study based on the intention to treat. The safety of NJ was
evaluated based on the compliance of the study participants and laboratory test performed on the
blood samples.
Results
One hundred and one adults with OA enrolled in the study and 82 [81%] completed the
intervention study. While several of those completing the intervention study complained about
the unpleasant taste of NJ, no one reported a side effect that precluded them from completing the
intervention study. Of the 19 who did not complete the intervention study, one moved from the
area, one was hospitalized for reasons unrelated to NJ and one was dropped from the intervention
study because she reported to the study coordinator that her primary care physician detected
asymptomatic hyperkalemia on a routine blood test. The remaining original study participants
either did not respond to multiple attempts to reach them or they rescheduled appointments but
failed to appear.
Table 1 displays the demographic characteristics of the study participants who completed
the intervention study. Almost 75% [74.4%] of the participants completing the intervention study
were female, half [50.0%] were obese [BMI > 30], 32.9% were overweight, and the vast majority
[93.9%] were Caucasian. A little over half of the completing intervention study participants were
partnered [59.0%], 62.2% did not graduate from college and 61.2% lived in households with
incomes > $40,000. Those who did not complete the study did not differ significantly from the
study group who finished the intervention study.
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Table 1. Demographic characteristic of study participants completing the 3-month trial

Gender

Male
Female

Variables

n
21
61

%
25.6
74.4

BMI

Normal
Overweight
Obese

14
27
41

17.1
32.9
50.0

Race

Caucasian
African American

77
5

93.9
6.1

Marital Status

Partnered

49

59.0

Not Partnered

34

41.0

Years of Formal
Education

< College Education
College Graduate

51
31

62.2
37.8

Household Income

< $40,000

31

38.8

> $40,000

49

61.2

Note: Age 62.1 ± 8.1 [mean ± SD]. Classification of BMI: normal [BMI < 24.9], over weight [BMI=25.0 to 29.9,
obese [BMI=30.0 or higher].

Of the 64 questions related to QoL, 49 [77%] had significant pre/post differences in the
mean as measured by an independent t-test. All the differences that achieved statistical
significance favored post intervention study improvement on the QoL measures. Table 2
summarizes the significant pre/post changes in the QoL measures for the body movement and
function measures. All of the movement and function questions were asked in terms of the past
month.
Table 3 displays the significant pre/post changes in the QoL measures for study
participants on the duration and severity of arthritis pain, psychological state measures of tension
and mood and satisfaction with QoL on multiple dimensions. All questions were asked in terms
of the past month. The results indicated that both the duration and the severity of pain were
reduced post intervention study and after the consumption of NJ over a three month time frame.
Regarding the psychological state measures of tension and mood the results also revealed that
both the level of tension experienced by OA patients participating in this intervention study as
well as the mood of the study participants improved. The results measuring the significant
pre/post differences in level of satisfaction on multiple dimensions indicated that there were
statistically significant pre/post positive differences in OA patient satisfaction with mobility,
walking and bending, hand and finger functions, arm function, self-care, household tasks, social
activity, arthritis pain, work, level of tension, and mood.
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The impact that the study participant’s OA had on multiple dimensions was also assessed
pre/post during the NJ clinical intervention study. The question was posed in terms of: How
much of your problem in each area of health was due to your arthritis? The significant results
are displayed in Table 4. For the dimensions of walking and bending, arthritis pain, work, level
of tension, and mood the impact of OA was significantly lessened.
Table 2. Pre/post assessment of QoL measures on movement and function
These questions were asked in terms of the past month.

Mobility level
Scale 1 [no days]-5 [all
days]

Walking and bending
Scale 1 [no days]-5 [all
days]

Arm function
Scale 1 [no days]-5 [all
days]

Self-care tasks
Scale 1[never]-5[always]
Household tasks
Scale 1[never]-5[always]

Pre-trial
[mean ± SD]

Post-trial
[mean ± SD]

p

How often were you out of the house for at
least part of the day?

4.350.78

4.560.74

< 0.05

How often were you able to do errands in
the neighborhood?

4.410.93

4.550.87

< 0.05

How often did someone have to assist you
to get around outside your home?

1.410.89

1.130.44

< 0.05

How often were you in bed or chair for
most or all of the day?

1.541.00

1.33.074

< 0.05

Did you have trouble doing vigorous
activities such as running, lifting heavy
objects, or participating in strenuous sports?

< 0.01
4.431.04

3.841.39

Did you have trouble either walking several
blocks or climbing a few flights of stairs?

3.66 1.42

2.791.43

<0.05

Did you have trouble bending, lifting or
stooping?

3.41 1.41

2.731.35

< 0.01

Did you have trouble either walking one
block or climbing one flight of stairs?

2.98 1.62

2.211.44

< 0.05

Could you easily put on a pullover sweater?

4.73 0.69

4.840.46

< 0.05

Could you easily comb or brush your hair?

4.74 0.73

4.900.29

< 0.05

Could you easily reach shelves that were
above your head?
Did you need help with a bath or shower?

4.211.10

4.520.82

< 0.05

1.27 0.71

1.120.55

< 0.01

Did you need help to get dressed?

1.210 .58

1.060.28

0.000

If you had the necessary transportation,
could you go shopping for groceries
without help

4.76 0.63

4.890.38
< 0.01

Support from Friends
and Family
Scale 1[never]-5[always]

Did you feel that your family or friends
understood the effects of your arthritis?

3.501.03

3.781.12
< 0.05
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Table 3. Pre/post assessment of arthritis pain, psychological state and satisfaction measures
All questions were asked in terms of the past month.
Pain measures

Pre-trial
[mean ± SD]

Post-trial
[mean ± SD]

p

How often did you have severe pain from your
arthritis?

3.37 1.17

2.571.13

< 0.05

How often did you have pain in two or more joints
at the same time?

3.61 1.23

3.091.14

< 0.05

How often did your morning stiffness last more
than one hour from the time you woke up?

3.161.28

2.341.23

< 0.05

How often did your pain make it difficult for you to
sleep?

2.95 1.20

2.321.05

< 0.05

4.010 .73

3.670.83

How often have you felt tense or high strung?

2.961.01

2.510.85

< 0.01

How often have you been bothered by nervousness
or your nerves?

2.720.97

2.290.85

< 0.01

3.370.83

3.610.74

3.350.79

3.660.77

< 0.01

3.820.79

4.040.69

< 0.01

2.630.81

2.210.78

2.620.88

2.210.85

< 0.01

How often did you feel that others would be better
off if you were dead?

1.430.82

1.280.71

< 0.01

How often did you feel so down in the dumps that
nothing would cheer you up?

1.720.92

1.410.70

< 0.01

Mobility level [example: do errands]

3.141.48

3.931.22

0.000

Walking and bending [example: climb stairs]

2.331.28

3.371.33

0.000

Hand and finger function [example: tie a bow]

3.881.26

4.430.93

< 0.01

Arm function [example: comb hair]

4.211.17

4.450.94

< 0.05

Household tasks [example: housework]

3.521.35

4.111.12

< 0.05

Social activity [example: visit friends]

4.081.24

4.341.11

0.000

Arthritis pain [example: joint pain]

2.111.15

3.141.23

0.000

Work [example: reduced hours]

3.411.32

4.181.15

0.000

Level of tension [example: felt tense]

3.261.27

4.021.05

0.000

Mood [example: down in the dumps]

3.631.12

4.131.03

0.000

Duration of
arthritis pain Scale
1 [no days] - 5 [all
days]

Severity of arthritis
pain Scale 1
[none] - 5 [severe]

How would you describe the arthritis pain you
usually had?

< 0.05

Psychological state measures scale 1 [never] - 5 [always]
Level of tension

How often have you felt relaxed and free of
tension?
How often have you felt calm and peaceful?
Mood

How often have you enjoyed the things you do?
How often have you been in low or very low
spirits?
How often did you feel that nothing turned out the
way you wanted it to?

< 0.01

< 0.01

Satisfaction measures scale 1[very dissatisfied] - 5 [very satisfied]
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Table 4. Pre/post assessment of impact of arthritis on area of health.
How much of your problem in each area of health was due to your
arthritis? This question was asked in terms of the past month.
Scale 1 [due entirely to my arthritis] – 6 [not a problem for me]

Pre-trial
[mean ± SD]

Post-trial
[mean ±
SD]

Walking And Bending [example: climb stairs]

2.381.35

2.781.53

< 0.05

Arthritis Pain [example: joint pain]

1.951.02

2.501.37

0.000

Work [example: reduced hours]

3.981.82

4.691.67

0.000

Level of tension [example: felt tense]

4.111.58

4.731.45

< 0.01

Mood [example: down in the dumps]

4.381.59

4.961.39

< 0.05

p

Table 5 presents data on study participants’ pre/post assessments of their current and
future health. Study participants indicated that they felt more positive about their current and
future health after the 3-month NJ intervention study. Study participants reported that
satisfaction with health improved, the degree to which health problems were attributed to OA
lessened, an assessment of self health in comparison to peer’s improved and the frequency to
taking medication for OA decreased post intervention study.
Table 5. Pre/post assessment of current and future health
Pre-trial
[mean ± SD]

Post-trial
[mean ±
SD]

p

How satisfied are you with your health now? Scale 1 [very
dissatisfied]-5 [very satisfied]

2.951.25

3.501.17

0.000

How much of your problem with your health now is due to your
arthritis? Scale 1 [due entirely to my arthritis] – 6 [not a problem for
me]

2.57.94

2.891.04

3.361.10

3.801.01

3.531.62

3.161.65

Considering all the ways that your arthritis affects you, how well are
you doing compared to other people your age? Scale 1 [very poorly]
– 5 [very well]
How often have you had to take medication for your arthritis? Scale 1
[no days]-5 [all days]

< 0.05

0.000

< 0.001

Patients were also assessed by pre/post intervention study laboratory tests [see Table 6].
With the exception of a very modest increase in creatinine levels, all other markers tested
remained unchanged
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Table 6. Pre/post laboratory results
Blood tests
Kidney function

Liver function

Lipoprotein profile
Inflammatory
marker
Plasma

Pre-trial

Post-trial

p

[meanSD]

[meanSD]

Urea nitrogen

15.44.1

14.85.5

> 0.05

Creatinine

0.910.16

0.970.19

< 0.05

BUN/Creatinine ratio
Total protein

16.9±25.6

15.3±5.7

7.11.6

6.90.4

> 0.05
> 0.05

Albumin

4.00.33

4.00.4

> 0.05

Bilirubin total

0.820.51

0.770.26

< 0.05

Bilirubin direct

0.140.1

0.120.06

> 0.05

ALP

74.230.0

73.529.3

> 0.05

AST

26.911.7

26.111.0

> 0.05

ALT

24.79.5

22.98.2

> 0.05

Total cholesterol

191.935.5

197.934.0

> 0.05

Triglyceride

120.171.6

121.880.9

> 0.05

Hs-C-reactive protein

4.94.99

4.23.6

> 0.05

Glucose (mg/dL)

67.08+/-27.4

66.21+/-24.5

> 0.05

Discussion
No ideal agent exists for the treatment of OA and while a number of OTC and prescription
medications are available, many patients turn to nutraceuticals for managing their OA. In a 2009
study, over 40% of those surveyed used an alternative OA treatment [28]. Despite their wide use,
many in the scientific community remain skeptical about alternative agents since there is often
little evidence to support their use. The study reported on here explored if NJ, one type of widely
used nutraceutical, improved the symptoms and QoL of adults with a diagnosis OA. The findings
of this 12-week pilot study intervention suggested that NJ may be an effective treatment for OA.
Our results revealed that study group scores improved in multiple dimensions including pain
symptoms, QoL measures, functional activity and psychological well being. An added benefit
was that research participants reported taking other supplemental OTC medications for OA less
frequently.
The improvement in pain scores and function found in this pilot study was not surprising
given that NJ has demonstrated effectiveness in both lab and animal models as a dual Cox-1 and
Cox-2 inhibitor and pain reliever. More interesting were the concomitant improvements in QoL,
psychological well being, satisfaction with personal health, and having a more positive outlook
on life. While this may be a secondary result of reduced pain symptoms and improved function,
a wide range of in vitro studies up-to-date indicate that NJ has biological activity that might yield
additional clinical benefit beyond its ability to relieve pain and improve function. These include
findings that demonstrate antioxidant activity [29], antimicrobial activity [30], xanthene oxidase
inhibition [31], and an inhibitory effect on lipoprotein lipase activity [32]. Recently Deng and
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colleagues demonstrated significant binding affinity of noni extract to the gamma-aminobutyric
acid A [GABAa] inhibitory neurotransmitter receptor which provides a possible biological
mechanism for the stress reducing benefits seen in this intervention study [22]. However, while
these and other studies demonstrate a biologic rationale for NJ, the importance of this pilot study
is that it is one of the few human studies that provide evidence of NJ’s potential benefit in a
clinical setting [33].
In addition to evaluating NJ’s benefits as a nutraceutical, this pilot study sought to
evaluate its tolerability and safety. In general, previous reports have indicated that NJ is safe and
that adverse effects consist mainly of benign gastrointestinal complaints occurring in less than
5% of cases [34]. Our findings suggest a similar safe profile for NJ with a high percentage
[>80%] adhering to and completing the study protocol. The most commonly reported complaint
was of its unpleasant taste and no one reported any rashes or allergic reactions. The issue of
whether NJ causes hepatotoxicity is debated in the literatures [35-40]. However, in this pilot
intervention study no evidence of liver toxicity was seen either clinically or in lab testing.
Hyperkalemia associated with NJ has also been reported previously [41], and one
individual enrolled in the intervention study reported asymptomatic hyperkalemia and was
dropped from the intervention study. Subsequent retesting revealed that the potassium level
returned to normal after one week. The potassium content in NJ is consistent with many
commonly consumed fruit juices and is significantly less than the amount found in higher
potassium foods such as bananas. However, our experience and the published case reports of
hyperkalemia associated with NJ suggests that NJ should be used cautiously in patients at risk
for hyperkalemia and that serum potassium may need to be monitored in individuals using NJ on
a consistent basis.
There are several important limitations to this study. First, the study was not a
randomized trial with a control group and enrolled only a relatively small number of subjects.
However, the study was not intended to be a definitive study but instead was planned as an
exploratory pilot intervention study to see if NJ merited further investigation. The study findings
appear sufficient to suggest that NJ may be a promising alternative to traditional treatment for
OA, meriting further investigation.
A second limitation was that only English speaking patients who had knee or hip pain
attributed to OA by their family physician were included in the study. Third, only people over
40 years of age were included. By excluding younger and non-English speaking patients, our
findings cannot be generalized to a broad spectrum of patients or those with other types of
musculoskeletal symptoms. Fourth, since significantly fewer men than women enrolled in the
intervention study, generalizing the findings to men should be done with caution. Fifth, we chose
not to use the diagnostic criteria of the American College of Rheumatology for OA of the hip
and knee, relying instead on confirmation from x-ray examination provided by a primary care
physician that the person enrolling in the study had OA. We believe, however, that our inclusion
criteria were more consistent with how NJ is used and were appropriate for a pilot intervention
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study. A sixth limitation centers on patients who were lost to follow up. We recognize that it is
possible that some of those individuals might have experienced side effects. However, we
believe it unlikely that any unreported side-effects represent a serious adverse reaction.
Throughout the intervention study, the coordinator requested that anyone experiencing problems
contact her and no one other than the individual with asymptomatic hyperkalemia did so. In
several attempts to contact those who dropped out, no one responded with a concern related to
NJ. Finally NJ [Tahitain Noni® juice] the product used in this intervention study may be unique
and other noni products may not yield similar benefit. Another limitation is that the findings rely
primarily on self-reported data and as such is subject to bias especially in an open label trial.
However, this study used validated reporting scales and in a disease such as OA where the goal
is to improve symptoms self report is a key marker for determining the efficacy of a treatment.
While open label, the authors believe the strength of the findings coupled with its relative safety
suggest that NJ merits further investigation in a blinded study.
Conclusion
The results from this 12-week pilot intervention study suggest that NJ is potential, safe, and
effective agent that may be able to reduce the symptoms of OA and help improve QoL. While
other studies have demonstrated the pharmacologic effects of NJ in vitro and in animal models,
few human studies have been conducted to support NJ benefits in a clinical setting. This pilot
study suggests the need for further rigorous examination to confirm the benefits seen here and to
ascertain the safety profile of NJ in a larger sample.
List of abbreviations:
NJ=Noni juice; QoL=Quality of Life; OA=Osteoarthritis; BMI=Body Mass Index; AIMS
2=Arthritis Impact Measurement Scales; SF-36 V2=Short Form-36 Version 2; NSAIDs=Nonsteroid anti-inflammatory drugs; hsCRP=High Sensitive C Reactive Protein; ROS=Reactive
Oxygen Species; LPO=lipid peroxides; GI= Gastrointestinal; Cox=Cyclooxy-genase; SD
rats=Sprague Dawley rats; GABAa=gamma-aminobutyric acid A; ALP=alkaline phosphatase;
AST= Aspartate aminotransferase; ALT=Alanine aminotransferase; OTC=Over-the-counter;
LPS=Lipopolysaccharides.
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